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Abstract
Background: In vitro cell systems together with omics methods represent promising alternatives to conventional
animal models for toxicity testing. Transcriptomic and proteomic approaches have been widely applied in vitro but
relatively few studies have used metabolomics. Therefore, the goal of the present study was to develop an
untargeted methodology for performing reproducible metabolomics on in vitro systems. The human liver cell line
HepG2, and the well-known hepatotoxic and non-genotoxic carcinogen 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD),
were used as the in vitro model system and model toxicant, respectively.
Results: The study focused on the analysis of intracellular metabolites using NMR, LC-MS and GC-MS, with
emphasis on the reproducibility and repeatability of the data. State of the art pre-processing and alignment tools
and multivariate statistics were used to detect significantly altered levels of metabolites after exposing HepG2 cells
to TCDD. Several metabolites identified using databases, literature and LC-nanomate-Orbitrap analysis were affected
by the treatment. The observed changes in metabolite levels are discussed in relation to the reported effects of
TCDD.
Conclusions: Untargeted profiling of the polar and apolar metabolites of in vitro cultured HepG2 cells is a valid
approach to studying the effects of TCDD on the cell metabolome. The approach described in this research
demonstrates that highly reproducible experiments and correct normalization of the datasets are essential for
obtaining reliable results. The effects of TCDD on HepG2 cells reported herein are in agreement with previous
studies and serve to validate the procedures used in the present work.
Background
Metabolomics has been defined as the quantitative mea-
surement of the multi-parametric metabolic response of
living systems to patho-physiological stimuli or genetic
modification [1]. It encompasses the qualitative and
quantitative measurement of metabolites interacting in a
biological system; targeted and untargeted strategies for
analysis of metabolites can be used. Targeted studies
focus on the analysis of a predefined list of metabolites,
whereas the initial objective of untargeted metabolomics
is to analyze as many non-predefined metabolites as
possible at the raw signal level. With the latter
approach, identification is only carried out on relevant
signals [2,3].
Recently, there has been an exponential growth in the
number of published papers concerning metabolomics
of a wide variety of systems [4-7]. Metabolomic
approaches have been used for toxicological studies [8].
However, in most cases, biofluids or tissues from in vivo
experiments have been analyzed [8,9]. Few toxicological
studies have been published that concern the profiling
of intracellular metabolites using in vitro cell culture
systems [10,11]
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Owing to ethical concerns (animal welfare) and cost
efficiency, there is a need to develop alternatives to con-
ventional toxicity testing incorporating animals [12].
Among these alternatives, in vitro systems are consid-
ered particularly promising [13,14]. Much research has
focused on the analysis of the effects of toxic com-
pounds using in vitro systems and omics techniques
[15-18]. However, transcriptomics and proteomics have
predominantly been used to elucidate the toxic mechan-
isms of the studied compounds.
The goals of the present work were two-fold. First, to
develop an untargeted in vitro cell system methodology
with reproducible metabolomics; second, to evaluate
toxicant-induced cell responses on metabolic levels with
regards to published data concerning the toxicant,
thereby substantiating the methodology. TCDD (2,3,7,8-
tetrabenzodi-p-dioxin) was chosen as the model toxic
compound as it has been widely studied in vivo and in
vitro [15,19,20], particularly in terms of its hepatotoxic,
carcinogenic and immunotoxic effects. Toxic effects of
dioxins mediated by the aryl hydrocarbon receptor
(AhR) include the wasting syndrome [21], the induction
of oxidative damage [22,23], hepatic injury and carcino-
genesis [24,25]. TCDD has also been reported to have
an anti-proliferative effect [26].
TCDD is an agonist of AhR, a cytosolic ligand-acti-
vated transcription factor. Upon activation, AhR
dimerizes with ARNT to form a heterodimer that binds
to DNA sequences called xenobiotic response elements
(XREs). Through such binding, AhR up-regulates the
expression of several downstream genes including those
encoding xenobiotic metabolizing enzymes such as
Phase I (e.g. cytochrome P450 monooxygenases) and
Phase II (e.g. glutathione S-transferases, sulfotrans-
ferases) biotransformation enzymes [27].
In this study, the human hepatoma cell line HepG2
was chosen for experiments concerning in vitro expo-
sure to TCDD as this compound is a well known liver
toxicant. HepG2 cells have preserved the activities of
several phase I and phase II enzymes [28]. Conse-
quently, HepG2 cells have been widely used as a model
for various omics studies concerning carcinogenicity and
hepatotoxicity [28-30]. Furthermore, this cell line has
been exploited for studying the effects of TCDD on
gene expression using transcriptomics [15-17,26].
For the untargeted metabolomics approach used in
this study, multiple complementary analytical techniques
were applied to polar and apolar cell lysate fractions, i.e.
NMR and GCMS to the apolar fraction, and NMR and
LCMS to the polar fraction. Data analysis was per-
formed using state-of-the-art software [31-33] for pre-
processing and alignment of data sets in combination
with multivariate statistical analysis and advanced identi-
fication technology.
Particular emphasis was placed on the repeatability of
experiments, reproducibility of metabolic changes, nor-
malization and validation of the results by literature
comparison.
Results
The advantages and limitations of omics techniques
applied to in vitro systems must be elucidated before in
vitro omics-based alternatives to conventional toxicity
studies are considered valid. The goal of the present
study was to develop a reproducible untargeted metabo-
lomics methodology for in vitro studies using the
HepG2 human hepatocarcinoma cell line exposed to
TCDD for 48 h.
Cell extracts containing intracellular metabolites were
separated into polar and apolar fractions and subjected
to 1D 1H-NMR and LC-MS or 1D 1H-NMR and GC-MS,
respectively. The majority of NMR and MS data obtained
were complementary in terms of their information con-
tent. Raw data were pre-processed and aligned using spe-
cific software enabling statistical analysis. Subsequently,
metabolites with significantly altered levels were identi-
fied using databases, literature and LC-nanomate-Orbi-
trap analysis. In this study, a particular focus concerned
the repeatability of experiments with HepG2 cells
obtained from different passages, and reproducibility of
biological replicates from the same passage, and normali-
zation of experimental data prior to comparison. Results
were compared with data from previous studies concern-
ing the effects of TCDD in non-metabolomics studies.
The first major problem addressed was the normaliza-
tion of chemical profiles. In this study, typical changes
in metabolite concentrations were between 20 and
100%. Compounds such as TCDD can influence overall
cell metabolism and cause a decrease in the rate of cell
proliferation. Therefore, the net effect of exposure can
be an overall decrease of metabolites because there is
less cell material. If this is not taken into account it will
dominate the metabolomics results and metabolic effects
may go undetected. Furthermore, in order to identify
statistically significant changes in metabolite concentra-
tions in the order of 20 to 100%, it was essential to have
multiple replicates.
Preliminary studies in our laboratory have shown that
the age of cell cultures (expressed as passage number)
could influence the magnitude of the effect of the expo-
sure on the cell metabolome. To address this issue,
HepG2 cells obtained from different passage numbers
were exposed to medium containing 10 nM TCDD or
the vehicle, DMSO, for a period of 48 h.
The apolar fraction
NMR analyses of the apolar fraction were performed
using the same deuterated chloroform. Therefore, the
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residual proton signal of chloroform was used as an
initial absolute internal standard. This allowed the
amount of lipids in solution to be estimated by calculat-
ing the ratio between the sum of the intensities of all
spectral signals (TS (total signals) = signals 1-22 in Fig-
ure 1) and the intensity of the residual CHCl3 signal
(not shown). These ratios are presented in the bar graph
of Figure 2, panel A. The TS/CHCl3 ratio was signifi-
cantly higher in DMSO samples than in TCDD samples,
indicating that the latter extracts contained less total
lipid.
TS predominantly represented membrane constituents
and triglycerides. Membranes are thought to be rela-
tively constant in terms of composition. Since mem-
brane constituents such as phospholipids (PL) are easily
detected in NMR-spectra, it was assumed that generic
phospholipid signals (such as signals 18 and 20 in Figure
1; backbone signal for non-lyso-PL and lyso-PL) could
be used as an internal measure for the amount of mem-
brane and thus for the number of cells. No specific sig-
nals representing lyso-PL could be detected in the NMR
spectrum, indicating that this species makes a negligible
contribution to the total phospholipids. This was corro-
borated by other known membrane constituents includ-
ing free cholesterol and polyunsaturated fatty acids,
which had constant ratios to the phospholipids (vide
infra). Normalization using a PL signal as an internal
standard gave excellent results when the spectra were
compared manually and when the PCA results were
considered. Since a PL signal is an internal standard, it
will reflect directly potential differences in biological
replicate flasks and may reflect possible small differences
in sample handling; therefore this normalization method
is better than using an external standard such as a cell
counting average obtained from additional cell culture
flasks. A better normalization allows for the detection of
smaller differences in concentrations of metabolites.
The ratio between the intensity of the PL signal (signal
20 in Figure 1) and CHCl3 (PL/CHCl3), presented in
Figure 2, panel B, was used to normalize the data before
multivariate analysis (MVA) was carried out. DMSO
control extracts contained more phospholipids, and
therefore more cells, than TCDD extracts (Figure 2).
The difference in the number of cells between TCDD-
exposed and control samples was significant for passage
numbers 30, 7 and 11. For passage numbers 11b and 17,
the differences in cell numbers did not reach
significance.
When scaling on PL signals (Figure 1), the signal cor-
responding to the bis-allylic protons of long chain poly-
unsaturated acyl groups (PUFA; signal 14 in Figure 1) at
2.84 ppm was not changed, indicating unaltered levels
of long chain PUFAs upon TCDD treatment. Further-
more, the signal relating to free cholesterol (signal 6 in
Figure 1) was not altered. Long chain PUFAs and free
cholesterol are important components of membranes
and it was expected that these components would corre-
late with membrane-related phospholipid signals.
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Figure 1 Total 1H NMR spectral signals of the apolar fraction of HepG2 cells exposed to TCDD (above) or the vehicle control DMSO
(below). For both treatments, four spectra were overlaid. The numbers of the signals correspond to those indicated in Table 1.
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Representative 1H NMR spectra replicates of apolar
extracts of HepG2 cells scaled on the PL signal are over-
laid in Figure 1, and the assignment of the signals is
given in Table 1. Figure 1 demonstrates an excellent
overlapping of biological replicates of controls and of
treated cell extracts. The main differences observed
between the treated and non-treated cell extracts were
related to triglyceride signals.
NMR data were pre-processed and aligned using a
program developed in-house [32,33]. The aligned finger-
print data were normalized using the PL/CHCl3 ratio
and exported in the form of spreadsheets for further
multivariate analysis. Figure 3A presents a PCA plot
(after pre-selection using 2Log transformation and an
ANOVA where p < 0.01) and demonstrates that the bio-
logical replicates of each sample were clustered (with or
without ANOVA pre-selection; data not shown). It is
remarkable that the passage number had an important
effect, reflecting the difference in the magnitude of the
effect of TCDD.
An alternative method of mining these normalized
data sets is to perform a PCA after consecutively doing
a 2Log transformation, a regrouping towards treatment
(TCDD) and control (DMSO), and an ANOVA (p <
0.01) (Figure 3B). From the underlying peak loadings
(additionally surviving a Bonferroni correction) responsi-
ble for the separation of samples in this PCA, it is possi-
ble to create a list of resonance positions that contribute
significantly to the observed separation between the
apolar fractions of cells exposed to TCDD and controls.
The expected decrease in triglyceride content, as
observed in Figure 1 (signal 17), was the major differ-
ence between the treated and non-treated samples (aver-
age ratio TCDD: DMSO = 0.5). This effect, clearly
observed during visual inspection of the NMR spectra,
differed significantly in the five experiments conducted.
Furthermore, the concentration of cholesterol ester was
decreased (average ratio TCDD: DMSO = 0.7) after
TCDD treatment (see Figure 1 signal 7). The decreases
in triglyceride and cholesterol ester content were
accompanied by a decrease in the intensity of the signals
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Figure 2 Ratios between the intensity of some NMR spectral signals. A: Ratio between the intensity of the total NMR spectral signals (TS)
and the intensity of the residual CHCl3 signal. B: Ratio between the intensity of the phospholipid signal in the NMR spectra (PL) and the
intensity of the residual CHCl3 signal.
Table 1 Assignment of the 1H NMR spectral signals of the
apolar fraction
Peak
number
Chemical shift
(ppm)
Assignmenta
1 0.68 Total cholesterol C18H3
2 0.85/0.86 Total cholesterol C26H3/C
27H3
3 0.86-0.91 Acyl groups CH3 (all except n-3)
4 0.92 Total cholesterol C21H3
5 0.98 n-3 acyl groups CH3
6 1.01 Free cholesterol C19H3
7 1.02 Esterified cholesterol C19H3
8 1.06-1.19 Multiple cholesterol protons
9 1.20-1.38 Acyl groups -(CH2)n-
10 1.50-1.65 Acyl groups -OCO-CH2-CH2- and
H2O
11 1.79-1.88 Multiple cholesterol protons
12 1.97-2.10 Acyl groups -CH2-CH=CH-
13 2.24-2.38 Acyl groups -OCO-CH2-
14 2.72-2.88 Acyl groups =HC-CH2-CH=
15 3.28-3.38 Choline N(CH3)3
16 3.90-4.02 Glycerophospholipids N-CH2
17 4.10-4.32 Glycerol backbone -CH2OCOR
18 4.33-4.43 Phosphatidylcholine PO-CH2
19 4.50-4.66 Esterified cholesterol C3H
20 5.17-5.24 Glycerophospholipid backbone
>CHOCOR
21 5.24-5.28 Glycerol backbone >CHOCOR
22 5.29-5.43 Acyl groups -CH=CH-
Numbers correspond to those in Figure 1.
aProtons assignment based on [81]
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related to unsaturated acyl groups (signals 12, 14 and 22
in Figure 1) due to allylic, bis-allylic and olefinic pro-
tons, respectively (average ratio TCDD: DMSO = 0.75).
The NMR data suggested that fatty acid composition
changed as a result of TCDD exposure. Therefore, a
GC-MS analysis of the fatty acid composition was per-
formed on the apolar fraction of the cells. Consistent
with the 1H NMR results, there was a difference in the
apolar fractions of cells exposed to TCDD and DMSO
with regard to the lipid content. Among the methyl
esters of fatty acids that were identified, the arachidonic
(AA, C20:4, n-6) and docosahexaenoic (DHA, C22:6, n-
3) PUFAs had the same profile within the samples. The
NMR data demonstrated that long chain PUFA content
correlates highly with PL. Therefore, samples were nor-
malized on the basis of the sum of the AA and DHA
signals. This normalized dataset was subjected to MVA
(2Log transformation, ANOVA with p < 0.01, followed
by a PCA; see Figure 4A). The PCA plot obtained was
similar to that obtained for 1H NMR.
In order to extract the most significant differences
between the exposures, the samples were re-grouped
B
A
Figure 3 PCA plots (after ANOVA p < 0.01) of the apolar fraction of HepG2 analyzed by 1H NMR and pre-processed and aligned using
a program developed in-house. A: Spheres with the same colour are technical replicates of the same sample per passage number. DMSO30:
green; TCDD30: red; DMSO7: lila; TCDD7: yellow; DMSO11b: light blue; TCDD11b: dark blue; DMSO17: orange; TCDD17: purple; DMSO11b: light
green; TCDD11b: white. B: Samples re-grouped with regard to treatment (irrespective of passage number). DMSO: green; TCDD: red.
A B
DMSO
TCDD
Figure 4 PCA plots (after ANOVA p < 0.01) after normalization of the apolar fraction of HepG2 cells analyzed by GC-MS. A: Spheres
with the same colour are technical replicates of the same sample per passage number. For denotation of the colours, see legend Figure 3. B:
Samples re-grouped with regard to treatment (irrespective of passage number). DMSO: green; TCDD: red.
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with regard to the treatments and re-analyzed (PCA,
after an ANOVA with p < 0.01; see Figure 4B and in
Additional File 1, Table S1).
The selection of peaks underlying the largest differ-
ences (and additionally surviving a Bonferroni correc-
tion) between the treatments were identified. Table 2
presents these fatty acids and their fold change and indi-
cates that the content of several fatty acids decreased
due to TCDD treatment. However, there was a slight
increase in the proportion of saturated fatty acids with
17 (average ratio TCDD: DMSO = 1.2) and 18 (average
ratio TCDD: DMSO = 1.3) carbon atoms, and an
increase in the proportion of an unidentified C18:2 iso-
mer (average ratio TCDD: DMSO = 1.3) (Table 2). The
decrease in several unsaturated groups observed in the
GC-MS data (Table 2) is in agreement with the NMR
data.
The polar fraction
The 1H NMR spectra of polar fractions were normalized
using the PL/CHCl3 ratio described above (obtained
from the corresponding apolar fractions) and presented
in Figure 2B. Representative normalized 1H NMR spec-
tra replicates of polar extracts from HepG2 cells were
overlaid (Figure 5) and the assignment of the signals is
presented in Table 3. The normalized pre-processed and
aligned NMR data were subjected to multivariate analy-
sis and the output (PCA plot after 2Log transformation
and ANOVA p < 0.01) is presented in Figure 6A. Differ-
ences between the polar fraction of cells exposed to
TCDD and those exposed to the control can clearly be
observed following the x-axis of the PCA. The y-axis
represents the differences between the different passage
numbers. To identify effects due to TCDD treatment, an
ANOVA (p < 0.01) (after 2Log transformation) with
regard to the treatment was performed, followed by
PCA (Figure 6B). From the underlying peak loadings
(additionally surviving a Bonferroni correction) responsi-
ble for the separation of samples in the PCA, it is possi-
ble to create a list of resonance positions that contribute
significantly to the observed PCA separation.
The normalized NMR data indicated that the levels of
several polar intracellular metabolites decreased due to
exposure to TCDD (Table 4). However, the intensities
of signals relating to taurine (average ratio TCDD:
DMSO = 1.4), citrate (average ratio TCDD: DMSO =
1.5), reduced glutathione, GSH (average ratio TCDD:
DMSO = 1.6) and oxidized glutathione, GSSG (average
ratio TCDD: DMSO = 1.3) increased. The GSH/GSSG
ratio increased by 18% due to TCDD exposure.
The same extracts were analyzed by LC-MS in order
to obtain more detailed information concerning the dif-
ferences in polar metabolite levels due to treatment.
The LC-MS data were pre-processed and aligned using
MetAlign, the program developed in-house [34]. The
aligned fingerprint data, in the form of generated
spreadsheets, were normalized using the PL/CHCl3 ratio
and subjected to 2Log transformation and ANOVA with
p < 0.01 followed by PCA (Figure 7A). The separation
between samples was dominated by passage number
rather than by treatment. In order to determine the
effect of TCDD on the polar fraction of the cells, the
samples of this dataset were re-grouped with regard to
treatment, and an ANOVA (p < 0.01) followed by a
PCA was performed after 2Log transformation (Figure
7B). From the peak loadings (additionally surviving a
Bonferroni correction) responsible for the separation of
samples in this PCA, it is possible to create a list of
masses that contributed significantly to the observed
PCA separation. This list of masses was screened for
molecular ions that showed at least a 1.2 fold change
due to the treatment. Table 4 lists the metabolites and
their fold change, as determined on the basis of frag-
mentation data from LC-nanomate-Orbitrap experi-
ments. Table 5 presents the exact experimental masses
Table 2 Apolar metabolites significantly affected by
TCDD (p < 0.01) and average fold change ratio between
treatments (TCDD vs. DMSO).
GC-MS Ratio TCDD/DMSO (RTD)
C12:0 0.78
C14:0 0.72
C14:1a 0.70
C14:1b 0.29
C16:1 (n-6) 0.63
C16:1 (n-9) 0.62
C17:0 1.20
C18:0 1.27
C18:1 (n-9) 0.78
C18:1c 0.72
C18:2a 0.71
C18:2b 0.63
C18:2c 1.29
C18:2d 0.64
C18:2e 0.63
C20:1b 0.79
C20:2a 0.74
C20:2b 0.70
C20:3a 0.80
C20:3b 0.64
C22:2 0.61
C22:3a 0.73
1H NMR Ratio TCDD/DMSO (RTD)
Total triglycerides 0.51
Total cholesterol ester 0.69
*Underscore letters indicate isomers (unidentified).
Individual passage number results are in Additional File 1 (Tables S3 and S4).
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of these metabolites, together with their obtained frag-
ments. A few metabolites remained unidentified.
There were significant increases in citric acid (average
ratio TCDD: DMSO = 1.7) and in GSSG (average ratio
TCDD: DMSO = 1.3) and GSH (average ratio TCDD:
DMSO = 1.2) contents in TCDD treated samples, in
general agreement with the 1H NMR data. However, the
GSH/GSSG ratio as determined from LC-MS data was
reduced, in contrast to the NMR data. Generally, NMR
data are more quantitative and reliable; furthermore, the
LC-MS data were acquired at a later date than the
NMR data. In a follow-up NMR study on the stability of
the sample, it was observed that the intensity of the
GSH signal decreased over time during storage whereas
the intensity of the GSSG signal increased (see Figure
S1 in Additional File 1). No other metabolic changes
were observed.
This reaction is known to be dependent on pH (i.e.
more prominent at higher pH). Therefore storage condi-
tions such as pH are important. NMR samples were
measured directly after adding phosphate buffer to the
freshly made extracts. In this study the UPLC-TOF/MS
samples were stored at -20°C without the phosphate
buffer and therefore under more acidic conditions (pH
ca. 5 as a result of the extraction conditions). The maxi-
mum storage time before UPLC-TOF/MS measurement
was 4 months. Under these storage conditions still some
conversion to of GSH to GSSG was present as deduced
from our experiments.
Discussion
The main aim of this study was to demonstrate the fea-
sibility of using metabolomics on intracellular com-
pounds of in vitro cell systems such as HepG2 cells, as
an alternative approach to studying the effects of toxi-
cants. We have demonstrated that reproducible results
can be obtained and that differences between controls
from different experiments can be subjected to statistical
analysis, but that caution is required with regard to
repeatability of experiments; generally, the same effects
are observed in different experiments but their magni-
tudes can differ. However, there is a consistent effect
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Figure 5 1H NMR spectra overlaid (4-fold) of the polar fraction of HepG2 cells exposed to DMSO (below) and TCDD (above). The
following metabolites are identified by using standards, from the literature and/or databases and the numbers of the signals correspond to
those indicated in Table 3. 1&2: leucine and isoleucine; 3: valine: 4: threonine: 5: lactale; 6: alanine; 7: putrescine; 8: acetate; 9: N-acetyl-aspartate;
10: glutamate; 11: glutamine; 12: reduced glutathione; 13: oxidized glutathione; 14: acetone; 15: citric acid; 16: creatine and/or phosphocreatine;
17: choline derivatives; 18: taurine; 19: glycine; 20: serine; 21: nucleotides derived from uridine (UMP, UDP, UTP); 22: nucleotides derived from
adenosine (AMP, ADP, ATP); 23: NAD+ and/or NADH; 24: tyrosine; 25: formate.
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(due to TCDD in this study) on metabolic profiles using
an untargeted approach. The changes in metabolite con-
centrations are minimal and can vary because of the
effect of the treatment on cell numbers. Therefore, nor-
malization (using PL and PUFA), as described above, is
crucial; so is having enough biological replicates to
ensure the accuracy of the data. Without normalization
or sufficient biological replicates, several of the meta-
bolic changes may not have been detected. In apparent
contradiction to the normalization using PL, it has been
reported that TCDD induces the expression of the phos-
pholipase A2a (PLA2a) gene in mouse hepatoma Hepa-
1c1c7 [35]. However, in this HepG2 study, degradation
of PL was not evident with regard to total PL. Further-
more, a parallel study using transcriptomics did not pro-
vide evidence of an effect of TCDD on PLA2a gene
expression in HepG2 cells; this supports the present
findings for HepG2 cells and supports the validity of the
chosen normalization method.
To substantiate the usefulness of the untargeted meta-
bolomics methodology, the observed changes in metabo-
lite levels were interpreted in the light of published data
concerning the effect of TCDD. Ultimately, this was the
validation of the procedures and protocols developed in
this study. In general, a decrease or increase of an intra-
cellular metabolite concentration is not necessarily an
indicator of flux. Actual metabolite levels depend on
how biochemical pathways/processes are regulated, how
metabolites in pathways interact and how fast and in
which directions reactions occur (kinetics). Cells tend to
balance their metabolism after perturbation in order to
maintain homeostasis. Therefore, it is likely that only
changes in the main pools of substrates in the cell are
measured when it is exposed to a toxicant. Inhibition/
activation of a pathway may lead to increased or
decreased levels of relevant pools of compounds. How-
ever, it is often difficult to determine whether inhibition
or activation is relevant by observing metabolite concen-
trations at one time point. As discussed in more detail
below, TCDD is known to have an effect on the prolif-
erative capacity, metabolism and antioxidant status of
the cell.
Effect on cell proliferation
Membrane constituents such as PL (Figure 2B) and free
cholesterol are present at lower levels in extracts
obtained after treatment with TCDD because there are
fewer cells in the culture, and are indicative of decreased
Table 3 Assignment of 1H NMR spectral signals of the polar fraction
Peak number Chemical shift (ppm) and multiplicityb,c Assignmenta
1 0.96 (t) Leucine
2 0.96, 1.05 (t) Isoleucine
3 1.01, 1.04 (d) Valine
4 1.32 (d) Threonine
5 1.33 (d) Lactate
6 1.48 (d) Alanine
7 2.00 (s), 2.48 (dd) N-acetyl-aspartate
8 2.08 (m), 2.34 (m) Glutamate
9 2.12 (m), 2,44 (m), 3.76 (m) Glutamine
10 2.18 (m), 2,57 (m), 2.98 (dd), 3.31 (dd), 3.78 (m) Oxidized glutathione
11 2.18 (m), 2,57 (m), 2.98 (dd), 3.78 (m), 4.58 (dd) Reduced glutathione
12 2.80 (dd) Aspartate
13 2.55 (d), 2.67 (d) Citrate
14 3.04 (s), 3.93 (d) Creatine/Phosphocreatine
15 3.23 (s) Choline derivatives
16 3.26 (t), 3.41 (t) Taurine
17 3.56 (s) Glycine
18 3.83 (dd), 3.98 (dd) Serine
19 6.10 (d), 6.14 (d), 8.18-8.22 (ov), 8.52 (s), 8.58 (s) Nucleotides derived from adenosine AXP (AMP, ADP and/or ATP)
20 5.95-5.99 (ov), 7.94-7.97 (ov), 8.09 (d) Nucleotides derived from uridine UXP (UMP, UDP and/or UTP)
21 6.01-6.20 (ov), 8.12-8.20 (ov), 8.79-8.88 (ov), 9.08-9.36 (ov) Nicotinamide adenine dinucleotides (NAD, NADH, NADP and/or NADPH)
22 6.99 (m), 7.20 (m) Tyrosine
23 8.46 (s) Formate
Numbers correspond with those in Figure 5.
aProtons assignment based on commercial standards, Human Metabolome Database [80] and on ref [82,83]
bs: singlet; d: doublet; dd: doublet/doublet; m: multiplet; ov: different overlapping signals
cOnly observed signals are shown
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proliferation during exposure; the anti-proliferative
effect of TCDD has been described previously [26]. The
lower levels of nucleotides in treated extracts indicate a
change in metabolites known to be involved in DNA
synthesis (Table 4).
Spermidine and N1-acetylspermidine were also found
in lower levels after TCDD treatment. Polyamines have
important functions in cell proliferation, differentiation
and apoptosis, and they are essential for hepatic growth
and regeneration [36]. Polyamines can be synthesized in
liver from agmatine (formed by decarboxylation of argi-
nine, via arginine decarboxylase) [37], but ornithine dec-
arboxylase (ODC) is the main enzyme responsible for
polyamine biosynthesis. ODC is involved in the conver-
sion of ornithine into putrescine, the precursor of other
polyamines [38,39]. Their catabolism, on the other hand,
is regulated by the enzymatic action of the polyamines
spermidine/spermine N1-acetyltransferase (cSAT) and
diamine oxidase [40].
ODC is induced during conditions where there is
enhanced gene activation and tissue growth. It has been
reported that ODC induction is inhibited by TCDD
[38,39].
Therefore, it is possible that induction of polyamine
synthesis in cultured HepG2 cells was inhibited by
TCDD, resulting in the low content of spermidine.
Effect on metabolism
Changes in metabolic profiles due to TCDD treatment
of HepG2 cells indicates major changes in the general
metabolism of these cells, which involves fatty acids,
amino acids and nucleotides. This is reminiscent of
wasting syndrome [21,41-43].
The decreases in triglycerides, cholesterol ester and
unsaturated fatty acids observed in the 1H NMR analysis
of the apolar fraction, together with the decreases in
several fatty acids observed in the GC-MS data, indicate
that under the conditions used in this study, TCDD
affected lipid metabolism.
Several in vivo studies [44-46] have demonstrated that
TCDD reduces the activity of enzymes involved in the
synthesis of de novo fatty acids (such as fatty acid
synthase, FAS and acetyl CoA carboxylase, AAC) and in
cholesterol biosynthesis (such as 3-hydroxy-methylglu-
taryl-CoA synthase) or the expression of genes encoding
these enzymes [41,42,47-49]. This effect, which was also
A
B
Figure 6 PCA plots (after ANOVA p < 0.01) after normalization of the polar fraction of HepG2 cells analyzed by 1H NMR and pre-
processed and aligned using a program developed in-house. A: Spheres with the same colour are technical replicates of the same sample
per passage number. For denotation of the colours, see legend to Figure 3. B: Samples re-grouped with regard to treatment (irrespective of
passage number). DMSO: green; TCDD: red..
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observed in experiments using mouse embryo fibroblasts
[50], supports the results presented here. In studies car-
ried out in vivo [49] and in vitro [50], it has been
reported that the effect of TCDD on the gene expres-
sion of enzymes involved in the de novo synthesis of
fatty acids is mediated by AhR.
Using GC-MS analysis it is possible to determine the
nature of the fatty acids that are most affected by expo-
sure to TCDD (Table 2). The levels of the majority of
fatty acids decreased upon treatment. However, the con-
tents of heptadecanoic (C17:0) and octadecanoic, i.e.
stearic (C18:0), acids were increased after exposure. The
increased percentage of saturated and the decreased per-
centage of mono-unsaturated fatty acids could be due to
the decreased expression of stearoyl-CoA-desaturase
(SCD1), as demonstrated in mouse embryo fibroblasts
after TCDD exposure [51]. SCD1 is the rate limiting
enzyme in the biosynthesis of mono-unsaturated fatty
acids and catalyzes the introduction of the cis double
bond in the Δ9 position of acyl CoA substrates [52].
Therefore, inhibiting the expression of SCD1 using
TCDD would partially explain the increased ratio
between saturated/monounsaturated fatty acids observed
in this study.
Pantothenic acid and AMP are metabolites found in
lower concentrations after exposure to TCDD (Table 4).
Pantothenic acid and AMP are two of the three precur-
sors for coenzyme A (CoA) synthesis. In general, during
fatty acid degradation and synthesis, CoA transports
fatty acids as acyl groups through repetitive degradative
or synthetic cycles.
Furthermore, decreases in the content of propionyl-
and butyryl-carnitines were observed when cells were
exposed to TCDD. These short chain acyl-carnitines are
metabolic products of the reaction of acyl CoA and car-
nitine, which is mediated by transferases in the mito-
chondria [53]. Formation of butyryl- and propionyl-
carnitines is favored when butyryl and propionyl-CoA
accumulate in the mitochondria owing to an increased
acyl-CoA/CoA ratio. In the case of propionyl-CoA, an
Table 4 Polar metabolites significantly affected by TCDD exposure.
Metabolite Change fold (1H NMR p < 0.01) Change fold (LC-MS p < 0.01)
Leucine, Isoleucine 0.69 0.64
Valine 0.72 0.69
Alanine 0.68 –
N-acetyl-aspartate 0.68 0.72
Glutamate 0.79 0.80
Glutamine 0.69 –
Glycine 0.72 –
Aspartate 0.66 –
Serine 0.65 –
Tyrosine 0.58 0.44
Proline – 0.54
Tryptophan – 0.79
Lactate 0.49 –
Spermidine – 0.24
N1-acetyl-spermidine – 0.59
Pantothenic acid – 0.62
Creatine/Phosphocreatine 0.66 –
Propyonylcarnitineb – 0.66
Butyrylcarnitine – 0.58
Nucleotides (AXP and UMP) 0.3-0.6 –
UMP – 0.71
AMP – 0.67
Oxidized glutathione 1.26 1.31
Reduced glutathione 1.58 1.23
Taurine 1.37 –
Citrate 1.46 1.68
UDP-N-acetyl-galactosamine/glucosamine* – 1.48
The fold changes are given as the ratio of the average content in TCDD and in DMSO. Individual passage number results are in Additional File 1 (Tables S5 and
S6).
*Tentatively identified
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increase in the catabolism of amino acids such as valine,
isoleucine and - indirectly - threonine and methionine
also favors its formation [54]. Changes in these carnitine
derivatives indicate that mitochondrial activity and
transport across mitochondrial membranes is affected
by CoA modulation and/or beta-oxidation of fatty acids.
The level of citrate increased, whereas the level of lac-
tate decreased, after exposure. Citrate is a feedback inhi-
bitor for glycolysis at the level of phosphofructokinase.
Lactate is a product of the conversion of pyruvate by
lactate dehydrogenase. These two metabolite changes
can indicate that glycolytic activity is lower because of
an influx of acetyl-CoA, for instance due to fatty acid
beta-oxidation. This is in agreement with the breakdown
of triglycerides and degradation of fatty acids, and chan-
ged activity in mitochondria (see above).
Together, these metabolic effects are reminiscent of a
wasting syndrome in which fatty acid metabolism and
energy metabolism (glycolysis, TCA cycle) are affected,
and the amino acid and nucleic acid pools are reduced.
These latter effects could contribute to the observed
decrease in cell proliferation. However, it is not clear
from the data whether beta-oxidation increased or if
fatty acids were transported out of the cell. In adipose
tissue, TCDD mobilizes fatty acids towards the plasma
[41,42,46,55,56]. An increase in amino acids circulating
in plasma owing to TCDD exposure has previously been
reported [57]. Therefore, the data could imply a shut-
down of the cells followed by the export of several
metabolites.
Several in vivo studies demonstrate an accumulation
of lipids in the liver [21,46,55,58], although the effects of
TCDD vary depending on the dose, exposure-time or
test animal used [41,44,45,59]. An increase in liver lipid
content is in contrast to the results found in this
research. However, in the published studies, a loss in
body fat is demonstrated, as is an increase in the serum
lipid content [41,42,46,55,56]. The increased serum lipid
content could increase uptake and accumulation of
extrahepatic lipids in liver [46,60]. This would explain
the occurrence of a fatty liver in vivo, and the differ-
ences in terms of lipid content between in vivo and in
vitro studies.
Effect on antioxidant status
NMR and LC-MS spectra demonstrated an increase in
reduced (GSH) and oxidized (GSSG) glutathione content
in samples treated with TCDD (Table 4). However, it
has been reported that GSH content decreases after
exposure to TCDD [61]. Furthermore, from the 1H
A
B
Figure 7 PCA plots (after ANOVA p < 0.01) after normalization of the polar fraction of HepG2 cells analyzed by LC-ToF-MS and pre-
processed and aligned using MetAlign (www.metalign.nl). A: Spheres with the same colour are technical replicates of the same sample per
passage number. For denotation of the colours, see legend Figure 3. B: Samples re-grouped with regard to treatment (irrespective of passage
number). DMSO: green; TCDD: red.
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Table 5 Masses and fragments of the masses of polar metabolites identified by means of LC-nanomate-Orbitrap
Compound Parent mass(M+1)1 Neutral
formula
Deviation (mDa)1 Fragments1
Proline 116.07046 C5H9NO2 -0.145 70.0649
86.0961
Leucine/Isoleucine 132.10191 C6H13NO2 0.005 69.0696
72.0805
Spermidine 146.16503 C7H19N3 -0.144 112.1117
158.0443
N-acetyl-aspartate 176.05542 C6H9NO5 0.091 134.0444
88.0390
165.0542
Tyrosine 182.08118 C9H11NO3 0.010 136.0754
119.0489
72.0806
Acetyl spermidine 188.17580 C9H21N3O 0.061 17.1019
171.1487
188.0702
L-tryptophan 205.09717 C11H12N2O2 0.016 146.0597
118.0648
193.0339
Citric acid (NH4+) 210.0606 C6H8O7 (+NH3) 0.002 175.0233
129.0179
173.0804
Propionylcarnitine 218.13869 C10H19NO4 0.005 155.0699
202.1070
Pantothenic acid 220.11792 C9H17NO5 -0.029 184.0963
90.0547
100,0754
Unknown2 230.18622 C11H24O2N3 -0.084 183.1121
213.1520
173.0802
Butyrylcarnitine 232.15416 C11H21NO4 -0.175 85.0281
Unknown2 250.03784 C6H12O3N4P2 -0.075 —
Unknown2 258.11020 C8H20O6NP 0.100 104.1067
C7H14ON8P 0.104
179.0414
162.0216
Glutathione reduced 308.09103 C10H17N3O6S -0.052 144.0110
116.0161
UMP 325.04318 C9H13N2O9P 0.037 97.0281
C10H14N5O7P 0.001 136.0615
AMP 348.07036 119.0349
296.0650
Unknown 425.10794 — — 350,0753
UDP-N-acetyl-galactosamine/glucosamine2 608.08866 C17H27N3O17P2 -0.186 405.0079
204.0861
Glutathione oxidized 613.15906 C20H32N6O12S2 -0.178 —
1Experimental value obtained in our measurements
2Tentatively assigned formula(e) and/or identification
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NMR data, it was observed that the GSH/GSSG ratio
increased ca. 20% with TCDD exposure. This ratio, con-
sidered a parameter for measuring the oxidative status
of a cell, has been reported to decrease in several in vivo
studies as a consequence of exposure to TCDD [23,61].
However, data are variable and some authors have
reported an increase in the GSH/GSSG ratio after mice
were treated with TCDD [22].
GSH acts as a nucleophilic “scavenger” of numerous
compounds and their metabolites via enzymatic and chemi-
cal mechanisms (converting electrophilic centers to
thioether bonds) and as a substrate in the glutathione per-
oxidase (GPx)-mediated reduction of lipid hydroperoxides
and of H2O2 to water [62,63]. As a consequence of this
reaction, GSH is oxidized to GSSG, which is in turn
recycled back to GSH via glutathione reductase (GR).
Therefore, any effect on the activity of GPx, GR or both
could affect the ratio between GSH and GSSG. Several in
vivo [61] and in vitro [64,65] studies have described the
inhibition of GPx activity in liver due to TCDD treatment.
Inhibition of the activity of this enzyme could theoretically
lead to an increase in the content of GSH and in the GSH/
GSSG ratio, as observed herein. However, it has been
reported that the activity of GPx in liver mitochondria of
mice exposed to TCDD is increased [22], but increased
activity of GR in liver mitochondria was also evident, possi-
bly explaining the increased GSH/GSSG ratio following
dioxin treatment. Some studies have demonstrated that
TCDD increases the activity of GR in liver cells [66],
whereas other authors describe the opposite effect [64].
In relation to the synthesis of GSH, Boverhof and co-
authors [41] demonstrated up-regulated expression of
the genes for enzymes involved in the synthesis of GSH
(such as glutamate-cysteine ligase, Gclc, and glutathione
synthase, Gss) after rats and mice were exposed to
TCDD. Increased synthesis of GSH could explain the
results. Boverhof and co-authors [41] described a down-
regulation of the genes associated with the metabolism
of glutamate and glycine, which are building blocks of
GSH. They suggested that this down-regulation could
be an adaptation of the cell to conserve these amino
acids for increased glutathione synthesis.
Other effects associated with TCDD treatment
Creatine is decreased in cells as a result of TCDD treat-
ment (Table 4). In relation to this, Boverhof and co-
authors [41] found that genes expressing guanidinoace-
tate N-methyltransferase (GAMT), one of the key
enzymes in the biosynthesis of creatine, are down-regu-
lated in liver after TCDD administration to rats. It has
been reported that GAMT deficiency is associated with
a reduction in body weight owing to reduced body fat
mass [67], which could be related to the aforementioned
in vivo effects of TCDD exposure.
The content of taurine, a non-protein sulfur-contain-
ing b-amino acid, is increased after the exposure of cells
to TCDD. Taurine plays an important role in several
biological processes including anti-oxidation, detoxifica-
tion, membrane stabilization and maintenance of osmo-
larity [68]. Moreover, it has been demonstrated that
there is a relationship between taurine and lipid metabo-
lism [69,70]. Taurine lowers hepatic triglyceride concen-
tration, reduces the synthesis of cellular cholesterol ester
and elevates hepatic free fatty acids. These effects are in
agreement with the results of the present study for
HepG2 cells exposed to TCDD. TCDD down-regulates
cysteine dioxygenase (CDO) [41,42,71,72], the first
enzyme in the conversion of cysteine to taurine. This
seems to conflict with the observation of higher taurine
levels after exposure to TCDD, but since the regulation
of taurine concentration is unknown, perhaps the
increased concentration of taurine after exposing cells
to TCDD is related to other mechanisms.
An increased signal (average ratio TCDD: DMSO =
1.5) tentatively assigned to uridine diphosphate-N-acet-
ylgalactosamine (UDP-NAcGal) and/or uridine dipho-
sphate-N-acetylglucosamine (UDP-NacGlu) was
observed after TCDD exposure (Table 4).
UDP-NAcGal and UDP-NacGlu are N-acetylhexosa-
mines involved in several biosynthetic reactions includ-
ing O-glycosylation of proteins on serine and threonine
residues. O-linked glycosylation involves the transfer of
the N-acetylhexosamine group from the UDP-acetylhex-
osamine, which is catalyzed by glycosyltransferases
[73,74].
Lower activity of these enzymes could theoretically
produce an increase in the levels of UDP-N-acetylhexo-
samines. In agreement with this, decreased expression of
GALNT1, the gene encoding the UDP-N-acetylgalacto-
samine transferase, was observed by Kim and co-authors
[75] after HepG2 cells were exposed to TCDD.
Changes in the intracellular levels of UDP-N-acetyl-
hexosamines, as observed in this study after exposure to
TCDD, may indicate that protein O-glycosylation is
affected. Altered expression levels of glycosylated pro-
tein have been described after TCDD exposure in vitro
[76].
We have no explanation for the decrease in concen-
tration of N-acetyl aspartate. This metabolite is normally
expressed at high concentrations in the brain and has
been implicated as an osmolyte [77] with the potential
to bind to calcium ions or metal ions [78].
Conclusions
The present study demonstrates that untargeted profil-
ing of the polar and apolar extracts of in vitro cultured
HepG2 cells using various analytical techniques is a fea-
sible approach to studying the effect of a toxicant,
Ruiz-Aracama et al. BMC Genomics 2011, 12:251
http://www.biomedcentral.com/1471-2164/12/251
Page 13 of 19
TCDD, on the cell metabolome. In the metabolomics
methodology used, sample protocols and handling were
minimized to enhance reproducibility. The results are
compatible with previously well-documented effects of
TCDD, in vitro and in vivo. This serves to validate the
metabolomics results produced in this study. This com-
bination of cell culture and metabolomics technology
(together with other -omics techniques) can contribute
to reducing the number of animals required for toxicity
studies.
This study is an example of how complementary ana-
lytical techniques (NMR, GCMS, LCMS) can be used on
the same samples and provide complementary data. The
untargeted nature of the experiments aids in finding dif-
ferences in profiles, which are then subjected to identifi-
cation approaches. As discussed, normalization and
sufficient biological replicates (and repeated experi-
ments) are essential for reliability (in terms of statistical
analysis) in detecting relatively small differences in ana-
lyte concentrations.
Maintaining homeostasis could be the driving force in
cells responsible for keeping concentration differences
small. The effects are predominantly centered on storage
pools of metabolites.
Methods
Chemicals
Minimal essential medium (MEM glutamax), non-essen-
tial amino acids, sodium pyruvate, penicillin/streptomy-
cin and fetal bovine serum were purchased from Gibco
BRL (Breda, The Netherlands). Ammonium acetate
(NH4Ac), sodium hydroxide (NaOH), sodium chloride
(NaCl), dipotassium hydrogenphosphate (K2HPO4),
monopotassium hydrogenphosphate (KH2PO4), boron
trifluoride (BF3), EDTA and deuterated chloroform
(CDCl3), deuterium oxide (D2O) and deuterated metha-
nol (CD3OD) were obtained from Merck (Darmstadt,
Germany); methanol (MeOH) and iso-octane from Bio-
solve (Valkenswaard, The Netherlands); DMSO and
TMSP from Sigma-Aldrich (St. Louis, MO, USA) and
TCDD (CAS no. 1746-01-6) from Cerilliant (Round
Rock, TX, USA). All chemicals and solvents were pur-
chased in the highest purity available. Ultra-pure water
was obtained using the PureLab equipment from Ross-
mark (Ede, The Netherlands).
Cell culture treatment and disruption
HepG2 cells were obtained from the ATCC (Rockville,
MD) and cultured in MEM glutamax supplemented
with 1% non-essential amino acids, 1% sodium-pyruvate,
1% penicillin/streptomycin and 10% fetal bovine serum
(FBS). The cells were incubated at 37°C with 5% CO2.
When the cell monolayer reached 80% confluency, the
medium was replaced with fresh medium with or
without TCDD. TCDD was administered to a final con-
centration of 10 nM by adding 60 μl of a solution of 2
μM of TCDD in DMSO to 12 ml of medium. In the
control treatments, cells were exposed to 12 ml of med-
ium to which 60 μl of DMSO had been added. The final
concentration of 10 nM TCDD was sub-cytotoxic and
has been used in previous omics studies [1,15] The
treatment of HepG2 cells with 10 nM TCDD and the
vehicle control (DMSO) was terminated after 48 h (as in
previous studies) by washing the cells several times with
ice-cold 0.9% NaCl in ultra-pure water and disrupting
them by osmotic shock with ice-cold ultra-pure water.
The cells were harvested using a cell scraper and subse-
quently treated ultrasonically to ensure total disruption.
The TCDD effect on the cell metabolome was studied
in five independent experiments, using five different pas-
sage numbers (p+7, p+11a, p+11b, p+17 and p+30). All
cells, except those in p+11b, originally came from the
same cryogenic vial; those in p+11b were obtained from
a second vial of frozen cells in order to check whether
there were differences between the same passage num-
bers from different vials (p+11a vs. p+11b). Four inde-
pendent biological replicates (i.e. tissue culture flasks)
were examined in each experiment.
A separate study - prior to this one - with additional
replicates was done to establish the suitability of the
normalization approach based on PL signals. This study
involved cell counting. In short, the cells were detached
from the flasks by trypsinization and counted using a
hemocytometer (Neubauer chamber). The results are
given in Table S2, Additional File 1.
Extraction of the apolar and polar fractions
The metabolomics study was performed on two differ-
ent fractions of the cells, one apolar fraction containing
the apolar metabolites (membranes and intracellular
lipids), and one polar fraction, containing the polar and
semi-polar intracellular metabolites. To extract these,
the disrupted cells were centrifuged (4°C) and the pellet
(apolar fraction) and supernatant (polar fraction) were
separated and processed.
Apolar fraction
The pellet was re-suspended in 1 M NH4Ac and freeze-
dried. Once dried, the residue was extracted three times
with 1 ml of CDCl3, after which the organic solvent was
evaporated under N2 flow. The dried extract was dis-
solved in 1 ml of CDCl3; an aliquot (0.6 ml) was used
for NMR analysis and the remaining sample was stored
at -20°C for GC-MS analysis.
Polar fraction
The supernatant containing the polar intracellular meta-
bolites was freeze-dried. The pellet was re-suspended in
1 ml of 100% CD3OD, dried with N2 and re-suspended
in 50% CD3OD/50% D2O. The solution was centrifuged
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to remove the proteins (in the pellet) and the superna-
tant was dried under N2 flow. The dry residue was dis-
solved in 1 ml of D2O. Some of the sample (350 μl) was
stored at -20°C for UPLC-TOF/MS analysis. To the
remainder, 1 M phosphate buffer (90:10; v: v; pH = 7)
in 99.95% D2O was added and used for NMR analysis.
Analysis of the polar and apolar fractions
NMR analysis
The samples were analyzed by NMR just after extrac-
tion. Some of these samples were also used for a follow-
up study with the aim of determining the stability of the
different metabolites over time. These samples were
stored at -20°C in phosphate buffer (pH = 7) for 9
months.
The 1H NMR spectra were recorded at 400.13 MHz at
300.0 (± 0.05) K on a Bruker Avance 400 narrow bore
using a 5.0-mm probe. The spectrometer settings were
2s relaxation delay; 1024 scans for the polar fraction
and 128 scans for the apolar fraction, with four dummy
scans in all cases; a spectral width of 5000 Hz; a 60
degree pulse; acquisition in 16 K data points. Prior to
data analysis, the raw NMR data were subjected to a
squared sine bell filter (shifted 1/2 pi), zero-filling to
128 K data points, Fourier transformation and phase
correction.
NMR raw data and the corresponding metadata are
provided as an additional file (see Additional file 2).
GC-MS analysis
Derivatisation A miniature scale BF3-mediated metha-
nolysis method for derivatizing fatty acids (for GC-MS)
was used. In brief: 132 μl of the apolar fraction was
dried under nitrogen. To this dry extract, 40 μl of 0.5 N
NaOH in MeOH was added. The capped vial was placed
in a pre-heated oven at 65°C for 30 minutes after which
50 μl of BF3 (20% in methanol) was added. After closing
it again, the vial was put in the oven for three minutes
at 65°C; 0.2 ml of iso-octane was added. The vial was
again closed and put in the oven for two minutes at 65°
C. After cooling, the volume was adjusted to 1 ml with
a saturated NaCl solution. This was shaken firmly and
the content was left to separate into two phases. The
vial was centrifuged at 2800 rpm and the upper phase
was carefully collected. For GC-MS analysis, 75 μl of the
iso-octane phase was transferred into a new vial and
kept at -20°C pending analysis.
GC-MS A Trace GC 2000 series gas chromatograph
interfaced with a Trace MS Plus mass spectrometer
(Thermo Finnigan, San Jose, CA) was used for GC/MS
analysis. Two μl of sample was injected using a PTV-
Splitless injection. For the separations, a RTX-5 column
(length 10 m, internal diameter 0.18 mm, stationary
phase film 0.20_m; Alltech, Breda, The Netherlands)
was used with helium as the carrier at a constant flow
of 1.3 ml/min. The GC temperature program was: 2
min at 80°C; increase temperature at 5.5°C min-1 to 185°
C followed by 3.5°C min-1 to 290°C. This latter tempera-
ture was kept for 12 min and afterwards it decreased by
120°C min-1 to 150°C. The GC-MS interface tempera-
ture was 280°C; the source temperature was 200°C.
Mass scanning in EI (electron impact) mode was carried
out for the range of 50-500 m/z at a scan time of 0.4
seconds. The detector voltage was set to 500 V and the
setting of the EI ionization source was 70 eV. All data
were collected consecutively in one analysis series to
minimize chromatography differences and the injection
sequence was randomized according to Vos and co-
authors [2].
Metadata for GS-MS files are provided as an addi-
tional file (see Additional file 2). Raw GS-MS data will
be provided by a download link on request
UPLC-TOF/MS analysis
The fraction containing the polar metabolites was stored
for a maximum of 4 months at -20°C (pH = 5) before
analysis by UPLC-TOF/MS. UPLC-TOF/MS samples
were diluted twice with D2O prior to analysis; formic
acid was added to a final concentration of 0.1%. The
injection sequence was randomized according to Vos
and co-authors [2]. The analyses were performed on a
LCT Premier LC-TOF-MS system (Waters, Milford,
MA, USA) equipped with a dual spray electrospray
source. The lock mass calibrant (leucine/enkephaline)
was measured every 10 scans. The gradient was pro-
vided by an UPLC system (model Acquity, Waters) with
a 150 mm × 2.1 mm UPLC BEH-C8 column with 1.7
μm particles (Waters).
The mobile phase consisted of water, acetonitrile and
formic acid (A:100/0/0.2 and B: 0/100/0.2). Gradient
elution was performed at 0.4 ml min-1. The initial elu-
ent composition, 100% A, was held for one min after
which the composition was changed to 85% A and
15% B in 14 min. Afterwards, the composition of B
was increased to 30% in 10 min and subsequently
increased again to 90% in three min; this composition
was maintained for five min. The injection volume was
10 μl. The effluent of the LC system was interfaced
directly with the TOF-MS, which was operated in posi-
tive mode polarity. A stable spray was obtained with a
capillary voltage of 2.5 kV, a source temperature of
120°C and desolvatation temperature of 350°C. The
desolvatation and cone gas flows were 600 and 50 L h-
1, respectively. The cone voltage was 50 V. Spectra
were collected in centroid mode from m/z 80 to 1500,
with a scan duration of 0.2 s. Accurate masses were
obtained after lock mass correction. The mass spectro-
meter was operated in W mode with the Dynamic
Range Enhancement turned on and the resolution was
8500 (FWHM).
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Metadata for LC-MS files are provided as an addi-
tional file (see Additional file 2). Raw LC-MS data will
be provided by a download link on request.”
LC-nanomate-Orbitrap analysis
Liquid Chromatography-Mass Spectrometry (LC-
PDA-MS) The system consisted of an Accela U HPLC
system (pump and auto sampler) equipped with an
Accela PDA with a one cm light Pipe flow cell (Ther-
moFisher Scientific) and coupled to a LTQ/Orbitrap
hybrid mass spectrometer (Thermo Fisher Scientific)
that was equipped with a chip-based nano-electrospray
ionization source (Triversa NanoMate (Advion BioS-
ciences). The sample (10 μl) was separated on a 150
mm × 2.1 mm UPLC BEH-C8 column with 1.7 μm par-
ticles (Waters). The flow rate was set at 0.4 ml min-1.
Isopropanol (60 μl min-1 of 100%) was added between
PDA and NanoMate via a T-junction to the LC flow to
ensure a stable nanospray. The sample was loaded with
100% eluent A (H2O/0.1% formic acid). The gradient
was the same as that used for the UPLC-TOF/MS analy-
sis. The PDA detector, placed between the analytical
column and the NanoMate, was programmed to acquire
data every second from 210 to 600 nm with a resolution
of 1 nm and 2 Hz sampling rate. The NanoMate source
was operated in the positive ionization mode with a
HD_A_384 chip with a spray voltage of 1.4 kV and 0.4
psi N2 gas. The NanoMate was used in the LC coupling
mode with fraction collection. The total flow (460 μl/
min) was split using capillary tubing for MS spray (480
nl/min) and for fractionation (459.5 μl/min). Fractions
were collected by the NanoMate from retention time 0.5
to 19.5 min in 3 s fractions (23 μl) in a 384 well plate
(twin tec, Eppendorf). The plate temperature was set at
10°C. After collection, extra isopropanol (5 μl) was
added. The plate was sealed to prevent evaporation of
the fractions. These fractions were used in the MSn
experiments. Parallel to the fractionation, the MS spray
from the NanoMate was used to record a full FTMS
scan (m/z 80-1000) with resolution of 15.000 (at m/z
400). Automatic tuning was carried out on m/z 566.89.
The full AGC target was set to 30000. The Orbitrap was
externally calibrated in positive mode using sodium for-
mate clusters in the range m/z 158.69-1110.79.
MSn by direct infusion The system consisted of a LTQ/
Orbitrap hybrid mass spectrometer (Thermo Fisher
Scientific) equipped with a chip-based nano-electrospray
ionization source (Triversa NanoMate, Advion BioS-
ciences). After manually selecting the masses of interest,
recorded in the full scan MS, the fractions containing
these masses were subjected to MSn fragmentation in
positive mode. Delivery of the sample to MS: The Nano-
Mate used a pipette tip to take the sample from a
selected well and infused this sample to the MS via the
spray nozzle on the chip. NanoMate parameters were:
spray voltage 1.7 kV and 0.6 psi N2 gas. The mass spec-
trometer was tuned on m/z 566.89. The full AGC target
was set to 30000. The Orbitrap was externally calibrated
in positive mode using sodium formate clusters in the
range m/z 158.69-1110.79. For performing the MSn
experiments in MS1 a window of 1 m/z was used to iso-
late the mass of interest. The resolution used in the
MS1 scan event was 60.000. For all dependent scan
events (MSn) a resolution of 15000 and normalized col-
lision energy 35% was used.
MSn description:
MS 1 Full scan with limited m/z range, m/z of inter-
est ± 0.5 m/z
MS 2 fragmentation of most intense m/z of MS1
MS 3 fragmentation of five most intense fragments
in MS2
MS 4 fragmentation of five most intense fragments
in MS3
MS 5 fragmentation of three most intense fragments
in MS4
Following the sample infusion and MS analysis, the
pipette tip was ejected and a new tip and nozzle
were used for each sample, thereby preventing any
cross-contamination or carry-over.
Data analysis
NMR data analysis
Pre-processing of the data and alignment A visual
inspection of the technical replicates (4-fold) of each
sample was carried out to ensure a high degree of
reproducibility. The NMR data were pre-processed and
aligned using a program developed in-house. This pro-
gram was described in the Materials and Methods sec-
tion of the paper by Lommen et al. [32], but has been
adapted to run under Windows.
Normalization The aligned fingerprint data in the form
of generated spreadsheets were normalized using factors
obtained from the scaling on the phospholipid signals of
the 1H NMR spectra of the apolar fraction (see
RESULTS section).
Statistical analysis The normalized spreadsheets of
both datasets were subjected to statistical analysis using
Genemaths XT [79]. Standard initial analysis entailed
performing a 2Log transformation and a PCA (average
of rows and columns subtracted). This was followed by
a 2Log transformation, a pre-selection of variables using
an ANOVA (p < 0.01) followed by a PCA (average of
rows and columns subtracted). An example of the effect
of the ANOVA is given in Figure S2 in the Additional
File 1. The grouping in the ANOVA was on the repli-
cates per treatment for each passage number of cells
when the effect of passage number as well as treatment
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was studied (10 groups with 5 replicates). The grouping
in the ANOVA was on all replicates per treatment irre-
spective of passage number when only the effect of
treatment was studied (2 groups of each 25 samples).
From the latter figure a selection of peak loadings -
underlying the separation by treatment in the PCA -
could be exported as described in [31] (an example is
given in Additional File 1, Figure S3); to check that the
numbers of variables selected exceeded that expected
purely by chance, table S1 was added in the Additional
File 1. Only differences with a fold change higher than
1.2 and surviving a Bonferroni false positive correction
were taken into account.
Identification of metabolites The identification of rele-
vant signals from the NMR data was carried out by
using commercially available standards and/or from lit-
erature and databases, such as HMDB [80].
MS data analysis
Pre-processing of the data and alignment A visual
inspection of the technical replicates (4-fold) of each
sample was carried out to ensure that high degree of
reproducibility. The GC-MS and LC-MS data were pre-
processed and aligned using MetAlign [31,34]. In short,
this software performs a baseline correction, accurate
mass calculation, data smoothing and noise reduction,
followed by alignment between chromatograms, generat-
ing data files that are reduced in size 100-1000 times.
The pre-processing and alignment parameters used have
been included as Figures S4 and S5 in Additional File 1.
Normalization
LC-MS data
The aligned fingerprint data of the polar fraction data-
set, in the form of generated spreadsheets, were normal-
ized using the phospholipid scaling factors obtained
from the 1H NMR spectra of the apolar fraction (see
RESULTS section).
GC-MS data
The identified peaks of GC-MS chromatograms were
manually integrated. This fraction was normalized by
scaling to the raw values of the integrals of docosahex-
aenoic and arachidonic methyl esters (see RESULTS
section).
Statistical analysis The same procedure as described in
the NMR section was used.
Identification of metabolites A method of facilitating
further analysis and identification was accomplished
using GM2MS, an application of MetAlign that re-cre-
ates “new chromatograms” that contain only the peaks
exported from the PCA selection [31]. Polar metabolites
were identified with commercially available standards,
with FT-MS/MS analysis and using databases, such as
the HMDB [80]. Fatty acids were identified using the
eluting order of the peaks and the NIST mass spectral
library.
Additional material
Additional file 1: PDF file containing Figures S1, S2, S3, S4 and S5
and Tables S1, S2, S3, S4, S5 and S6, mentioned in the text.
Additional file 2: Metadata and NMR raw data: ZIP file containing:
-All NMR raw data (in JCAMP-DX format “.dx”) -The metadata on NMR
(polars & apolars), LC-MS and GC-MS data sets (as Tab delimited files “.
txt”).
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